• Je něco špatně v tomto záznamu ?

Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma

B. Havlínová, I. Součková, K. Kopřivová, J. Doležal

. 2024 ; 17 (1) : 147. [pub] 20240523

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013877

Grantová podpora
480122 Charles University, Faculty of Medicine in Hradec Králové

Differentiated thyroid cancer is the most common endocrinological malignancy. Radioiodine treatment has a clear benefit in locally aggressive and metastatic cancers. There are discussions about long-term and acute adverse events.Anti-Müllerian hormone is regarded as the best endocrine marker for evaluating the physiological loss of oocytes in healthy women with regard to age. The impact of radioiodine treatment on anti-Müllerian hormone levels has been more significantly reported in patients over 35 years of age. About reproductive dysfunction, calculations of individual absorbed doses of radioiodine in ovaries after thyroid cancer therapy have not been performed yet. The aim of our ongoing prospective study is to determine serum anti-Müllerian hormone to estimate ovarian reserve for premenopausal women treated with radioiodine and to compare anti-Müllerian hormone levels before and after radioiodine treatment. Predicting radioiodine side effects by evaluating a simple serum biomarker may help to select an appropriate treatment strategy for young women planning pregnancy, specifically in the assessment of ovarian reserve and premature ovarian failure with early onset of menopause.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013877
003      
CZ-PrNML
005      
20240905134107.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13104-024-06802-y $2 doi
035    __
$a (PubMed)38783369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Havlínová, Barbora $u The 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, Sokolská 581, Hradec Králové, 50005, Czech Republic. barbora.havlinova@fnhk.cz $1 https://orcid.org/0000000223573763
245    10
$a Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma / $c B. Havlínová, I. Součková, K. Kopřivová, J. Doležal
520    9_
$a Differentiated thyroid cancer is the most common endocrinological malignancy. Radioiodine treatment has a clear benefit in locally aggressive and metastatic cancers. There are discussions about long-term and acute adverse events.Anti-Müllerian hormone is regarded as the best endocrine marker for evaluating the physiological loss of oocytes in healthy women with regard to age. The impact of radioiodine treatment on anti-Müllerian hormone levels has been more significantly reported in patients over 35 years of age. About reproductive dysfunction, calculations of individual absorbed doses of radioiodine in ovaries after thyroid cancer therapy have not been performed yet. The aim of our ongoing prospective study is to determine serum anti-Müllerian hormone to estimate ovarian reserve for premenopausal women treated with radioiodine and to compare anti-Müllerian hormone levels before and after radioiodine treatment. Predicting radioiodine side effects by evaluating a simple serum biomarker may help to select an appropriate treatment strategy for young women planning pregnancy, specifically in the assessment of ovarian reserve and premature ovarian failure with early onset of menopause.
650    _2
$a lidé $7 D006801
650    12
$a antimülleriánský hormon $x krev $7 D054304
650    12
$a radioizotopy jodu $x terapeutické užití $7 D007457
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory štítné žlázy $x radioterapie $x krev $7 D013964
650    12
$a ovariální rezerva $x účinky léků $7 D065851
650    _2
$a dospělí $7 D000328
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Součková, Ilona $u Department of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
700    1_
$a Kopřivová, Kateřina $u Department of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
700    1_
$a Doležal, Jiří $u Department of Nuclear Medicine, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
773    0_
$w MED00165970 $t BMC research notes $x 1756-0500 $g Roč. 17, č. 1 (2024), s. 147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38783369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134101 $b ABA008
999    __
$a ok $b bmc $g 2143596 $s 1225743
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 17 $c 1 $d 147 $e 20240523 $i 1756-0500 $m BMC research notes $n BMC Res Notes $x MED00165970
GRA    __
$a 480122 $p Charles University, Faculty of Medicine in Hradec Králové
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace